Literature DB >> 6885791

Studies on the mechanism of thrombin. Interaction with fibrin.

M Kaminski, J McDonagh.   

Abstract

Fibrin monomer Sepharose was used to investigate the interactions of thrombin with fibrin. Thrombin binding was found to be reversible and saturable and to depend on the thrombin: fibrin ratio. Scatchard analysis indicated a single class of binding sites with K alpha = 4.9 X 10(5) M-1. Ca2+ ions caused rapid desorption and elution of thrombin from fibrin monomer, and the Ca2+ concentration needed for maximal desorption depended on the fibrin:thrombin ratio. Mg2+, Mn2+, and Sr2+ also released thrombin from fibrin monomer but not as efficiently as Ca2+. These results indicate that divalent metal ions induce a physical change in fibrin monomer which results in desorption of thrombin. Thrombin binding to fibrin in a gel was compared to binding to fibrin monomer. These studies showed that as fibrin monomers polymerize to form the gel network, thrombin is released. Under static conditions the released thrombin remains associated with the gel because diffusion is limited by the gel. However, the thrombin can be readily removed when buffer is allowed to flow through the gel. These results lead to the possibility that thrombin binding to fibrin monomer and its subsequent release, either by Ca2+ or by polymerization, may have important consequences for regulating the effective thrombin concentration in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6885791

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Crystal structure of the complex between thrombin and the central "E" region of fibrin.

Authors:  Igor Pechik; Joel Madrazo; Michael W Mosesson; Irene Hernandez; Gary L Gilliland; Leonid Medved
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

2.  Hierarchies in the binding of human factor XIII, factor XIIIa, and endothelial cell transglutaminase to human plasma fibrinogen, fibrin, and fibronectin.

Authors:  K E Achyuthan; T C Rowland; P J Birckbichler; K N Lee; P D Bishop; A M Achyuthan
Journal:  Mol Cell Biochem       Date:  1996-09-06       Impact factor: 3.396

3.  Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B.

Authors:  R M Senior; W F Skogen; G L Griffin; G D Wilner
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

4.  Identification of a thrombin sequence with growth factor activity on macrophages.

Authors:  R Bar-Shavit; A J Kahn; K G Mann; G D Wilner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

5.  Inhibited thrombins. Interactions with fibrinogen and fibrin.

Authors:  M Kaminski; J McDonagh
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

6.  Identification of intracellular factor XIII in human monocytes and macrophages.

Authors:  P Henriksson; S Becker; G Lynch; J McDonagh
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

7.  Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network.

Authors:  H Bänninger; B Lämmle; M Furlan
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

8.  Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr.

Authors:  J Koopman; F Haverkate; S T Lord; J Grimbergen; P M Mannucci
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

9.  CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen.

Authors:  J D Loike; B Sodeik; L Cao; S Leucona; J I Weitz; P A Detmers; S D Wright; S C Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

10.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.